Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Active, not recruiting · NCT06055465 · Registry updated 2026-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-06-18 | NCT06055465 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese University of Hong Kong | 480 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Clinical Oncology, Prince of Wales Hospital | Hong Kong | Hong Kong | 16 |
| Department of Clinical Oncology, Queen Elizabeth Hospital | Hong Kong | Hong Kong | 1 |
| Department of Clinical Oncology, Tuen Mun Hospital | Hong Kong | Hong Kong | 2 |
| Department of Oncology, Princess Margaret Hospital | Hong Kong | Hong Kong | 2 |